European Alpha-1 Research Collaboration (EARCO) in Portugal: The Future Is Happening

Maria Sucena; Raquel Marçôa; Catarina Guimarães

doi:10.20344/amp.20953

European Alpha-1 Research Collaboration (EARCO) in Portugal: The Future Is Happening

Authors

Maria Sucena Pulmonology Department. Hospital de Santo António. Unidade Local de Saúde de Santo António. Porto.
Raquel Marçôa Pulmonology Department. Hospital Eduardo Santos Silva. Unidade Local de Saúde Gaia e Espinho. Vila Nova de Gaia.
Catarina Guimarães Pulmonology Department. Hospital da Senhora da Oliveira. Unidade Local de Saúde Alto Ave. Guimarães.

DOI:

https://doi.org/10.20344/amp.20953

Keywords:

alpha 1-Antitrypsin Deficiency, Portugal, Registries

Abstract

N/A.

Downloads

Download data is not yet available.

References

Cortes-Lopez R, Barjaktarevic I. Alpha-1 antitrypsin deficiency: a rare disease? Curr Allergy Asthma Rep. 2020;20:51. DOI: https://doi.org/10.1007/s11882-020-00942-4

Blanco IB, Diego I, Pérez -hS, Lara B, Maldonado F, Esquinas C, et al. Alpha-1 antitrypsin Pi*SZ genotype: estimated prevalence and number of SZ subjects worldwide. Int J Chron Obstruct Pulmon Dis. 2017;12:1683-94. DOI: https://doi.org/10.2147/COPD.S137852

Meira L, Boaventura R, Seixas S, Sucena M. Alpha-1 antitrypsin deficiency detection in a Portuguese population. COPD. 2018;15:4-9. DOI: https://doi.org/10.1080/15412555.2017.1414779

Spínola C, Bruges-Armas J, Pereira C, Brehm A, Spínola H. Alpha-1-antitrypsin deficiency in Madeira (Portugal): the highest prevalence in the world. Respir Med. 2009;103:1498-502. DOI: https://doi.org/10.1016/j.rmed.2009.04.012

Miravitlles M, Chorostowska-Wynimko J, Ferrarotti I, McElvaney NG, O’Hara K, Stolk J, et al. The European Alpha-1 Research Collaboration (EARCO): a new ERS clinical research collaboration to promote research in alpha-1 antitrypsin deficiency. Eur Respir J. 2019;53:1900138. DOI: https://doi.org/10.1183/13993003.00138-2019

Greulich T, Altraja A, Barrecheguren M, Bals R, Chlumsky J, Chorostowska-Wynimko J, et al. Protocol for the EARCO registry: a pan-European observational study in patients with α1-antitrypsin deficiency. ERJ Open Res. 2020;6:00181-2019. DOI: https://doi.org/10.1183/23120541.00181-2019

Miravitlles M, Turner AM, Torres-Duran M, Tanash H, Rodríguez-García C, López-Campos JL, et al. Clinical and functional characteristics of individuals with alpha-1 antitrypsin deficiency: EARCO international registry. Respir Res. 2022;23:352. DOI: https://doi.org/10.1186/s12931-022-02275-4

Lopes AP, Mineiro MA, Costa F, Gomes J, Santos C, Antunes C, et al. Portuguese consensus document for the management of alpha-1-antitrypsin deficiency. Pulmonology. 2018;24:s1-21. DOI: https://doi.org/10.1016/j.pulmoe.2018.09.004

Sucena M, Gomes J, Guimarães C, Miravitlles M. Implementation of European Alpha-1 Research Collaboration (EARCO) in Portugal: the future starts now. Pulmonology. 2020;26:181-3. DOI: https://doi.org/10.1016/j.pulmoe.2020.01.003

Barrecheguren M, O’Hara K, Wilkens M, Boyd J, Kolda E, Lara B, et al. Research priorities in α1- antitrypsin deficiency: results of a patients’ and healthcare providers’ international survey from the EARCO Clinical Research Collaboration. ERJ Open Res 2020;6:00523-2020. DOI: https://doi.org/10.1183/23120541.00523-2020

Greulich T, Albert A, Cassel W, Boeselt T, Peychev E, Klemmer A, et al. Opinions and attitudes of pulmonologists about augmentation therapy in patients with alpha-1 antitrypsin deficiency. a survey of the EARCO group. Int J Chron Obstruct Pulmon Dis. 2022;17:53-64. DOI: https://doi.org/10.2147/COPD.S346051

Downloads

Published

2024-11-04

How to Cite

Sucena M, Marçôa R, Guimarães C. European Alpha-1 Research Collaboration (EARCO) in Portugal: The Future Is Happening. Acta Med Port [Internet]. 2024 Nov. 4 [cited 2026 Jun. 4];37(11):754-6. Available from: https://www.actamedicaportuguesa.com/revista/index.php/amp/article/view/20953

Download Citation

Issue

Vol. 37 No. 11 (2024): November

Section

Perspective

License

This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.

All the articles published in the AMP are open access and comply with the requirements of funding agencies or academic institutions. The AMP is governed by the terms of the Creative Commons ‘Attribution – Non-Commercial Use - (CC-BY-NC)’ license, regarding the use by third parties.

It is the author’s responsibility to obtain approval for the reproduction of figures, tables, etc. from other publications.

Upon acceptance of an article for publication, the authors will be asked to complete the ICMJE “Copyright Liability and Copyright Sharing Statement “(http://www.actamedicaportuguesa.com/info/AMP-NormasPublicacao.pdf) and the “Declaration of Potential Conflicts of Interest” (http:// www.icmje.org/conflicts-of-interest). An e-mail will be sent to the corresponding author to acknowledge receipt of the manuscript.

After publication, the authors are authorised to make their articles available in repositories of their institutions of origin, as long as they always mention where they were published and according to the Creative Commons license.